Physician profile
Renuka Sothinathan
NPI 1225124779
$67,845.57
in general payments reported to CMS, 2019-2025
37 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $8,037 · 2021: $8,852 · 2022: $7,429 · 2023: $8,433 · 2024: $19K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,100 · Consulting Fee: $5,900 · Travel and Lodging: $4,825 · Food and Beverage: $4,168 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,300.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,100.00 |
| Consulting Fee | $5,900.00 |
| Travel and Lodging | $4,824.78 |
| Food and Beverage | $4,168.08 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $43,551.58 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $15,839.68 | 2019-2022 | |
| Kaneka Medical America LLC | $3,348.00 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $588.00 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $373.37 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $301.05 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $282.91 | 2019-2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $267.12 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $260.65 | 2019-2025 | Velphoro |
| Mallinckrodt Enterprises LLC | $246.91 | 2019 | |
| Ani Pharmaceuticals, INC. | $244.44 | 2022-2023 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $232.93 | 2019-2022 | |
| Horizon Therapeutics Plc | $230.16 | 2020-2022 | |
| Glaxosmithkline, LLC. | $187.98 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $184.65 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $183.11 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.51 | 2021-2023 | |
| Amgen INC. | $166.04 | 2019-2025 | Uplizna |
| Recor Medical INC | $156.65 | 2025 | Paradise Ultrasound Renal Denervation System |
| Arbor Pharmaceuticals, INC. | $148.84 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $138.60 | 2019 | |
| Aurinia Pharma U.S., INC. | $121.26 | 2022-2023 | Lupkynis |
| Janssen Pharmaceuticals, INC | $104.06 | 2022 | |
| Novo Nordisk INC | $94.17 | 2025 | Ozempic, Rybelsus, Rivfloza |
| Takeda Pharmaceuticals U.S.A., INC. | $86.59 | 2020-2025 | Gattex |
| Ardelyx, INC. | $82.09 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $71.43 | 2019-2020 | |
| Shire North American Group INC | $44.31 | 2019 | |
| Scpharmaceuticals INC. | $26.83 | 2025 | |
| Medtronic, INC. | $26.05 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.96 | 2021 | |
| Nxstage Medical, INC. | $16.62 | 2025 | Nxstage System One |
| Genentech USA, INC. | $14.53 | 2025 | Gazyva |
| Hikma Pharmaceuticals USA | $14.31 | 2020 | |
| Amarin Pharma, INC. | $11.18 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renuka Sothinathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.